Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial?

      The advent of anti-HER2 agents dramatically changed the natural history of HER2-positive breast cancer. Strong research efforts have brought, starting with trastuzumab, a class of anti-HER2–targeted therapies, which includes, at present, four approved agents in the metastatic setting: trastuzumab, lapatinib, pertuzumab and trastuzumab emtansine (T-DM1). These agents have led to doubling median overall survival (OS), which is currently longer than 55 months, and more than tripling the 5-year survival rate [
      • Swain S.M.
      • Baselga J.
      • Kim S.B.
      • et al.
      Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Swain S.M.
        • Baselga J.
        • Kim S.B.
        • et al.
        Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
        N Engl J Med. 2015; 372: 724-734
        • Verma S.
        • Miles D.
        • Gianni L.
        • et al.
        Trastuzumab emtansine for HER2-positive advanced breast cancer.
        N Engl J Med. 2012; 367: 1783-1791
        • Krop I.E.
        • Kim S.B.
        • Gonzalez-Martin A.
        • et al.
        Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
        Lancet Oncol. 2014; 15: 689-699
        • Krop I.E.
        • Kim S.B.
        • Martin A.G.
        • et al.
        Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
        Lancet Oncol. 2017; 18: 743-754
        • Montemurro F.
        • Ellis P.
        • Anton A.
        • et al.
        Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1.
        Eur J Cancer. 2019; 109: 92-102
        • Dieras V.
        • Harbeck N.
        • Budd G.T.
        • et al.
        Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.
        J Clin Oncol : Off J Am Soc Clin Oncol. 2014; 32: 2750-2757
        • von Minckwitz G.
        • Huang C.S.
        • Mano M.S.
        • et al.
        Trastuzumab emtansine for residual invasive HER2-positive breast cancer.
        N Engl J Med. 2019; 380: 617-628
        • Gebhart G.
        • Lamberts L.E.
        • Wimana Z.
        • et al.
        Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
        Ann Oncol : Off J Eur Soc Med Oncol/ESMO. 2016; 27: 619-624
        • Beck A.
        • Goetsch L.
        • Dumontet C.
        • Corvaia N.
        Strategies and challenges for the next generation of antibody-drug conjugates.
        Nat Rev Drug Discov. 2017; 16: 315-337
        • Bianchini G.
        • Gianni L.
        The immune system and response to HER2-targeted treatment in breast cancer.
        Lancet Oncol. 2014; 15: e58-e68
        • Collins D.M.
        • O'Donovan N.
        • McGowan P.M.
        • O'Sullivan F.
        • Duffy M.J.
        • Crown J.
        Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.
        Ann Oncol : Off J Eur Soc Med Oncol/ESMO. 2012; 23: 1788-1795
        • Nordstrom J.L.
        • Gorlatov S.
        • Zhang W.
        • et al.
        Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties.
        Breast Cancer Res. 2011; 13: R123
        • Curtis C.
        • Shah S.P.
        • Chin S.F.
        • et al.
        The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
        Nature. 2012; 486: 346-352
        • Hendrickx W.
        • Simeone I.
        • Anjum S.
        • et al.
        Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis.
        OncoImmunology. 2017; 6: e1253654
        • Kim A.
        • Lee S.J.
        • Kim Y.K.
        • et al.
        Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value.
        Sci Rep. 2017; 7: 11671
        • Luen S.J.
        • Salgado R.
        • Fox S.
        • et al.
        Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
        Lancet Oncol. 2017; 18: 52-62
        • Stagg J.
        • Loi S.
        • Divisekera U.
        • et al.
        Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.
        Proc Natl Acad Sci U S A. 2011; 108: 7142-7147
        • Muller P.
        • Kreuzaler M.
        • Khan T.
        • et al.
        Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.
        Sci Transl Med. 2015; 7: 315ra188
        • Loi S.
        • Giobbie-Hurder A.
        • Gombos A.
        • et al.
        Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
        Lancet Oncol. 2019 Mar; 20: 371-382
        • Rius Ruiz I.
        • Vicario R.
        • Morancho B.
        • et al.
        p95HER2-T cell bispecific antibody for breast cancer treatment.
        Sci Transl Med. 2018; 10
        • Slaga D.
        • Ellerman D.
        • Lombana T.N.
        • et al.
        Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3.
        Sci Transl Med. 2018; 10
        • Moulder S.L.
        • Borges V.F.
        • Baetz T.
        • et al.
        Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2(+)-advanced solid tumors, with an expansion cohort in HER2(+) metastatic breast cancer (MBC).
        Clin Cancer Res : Off J Am Assoc Cancer Res. 2017; 23: 3529-3536
        • Awada A.
        • Colomer R.
        • Inoue K.
        • et al.
        Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial.
        JAMA Oncol. 2016; 2: 1557-1564

      Linked Article